Вопросы вирусологии. 2017; 62: 65-72
Активация парамиксовирусов протеазами в культурах нормальных и раковых клеток
https://doi.org/10.18821/0507-4088-2017-62-2-65-72Аннотация
Список литературы
1. Lamb R.A., Parks G.D. Paramyxoviridae: their viruses and their replication. In: Fields B.N., Knipe D.M., Howley P.M., eds. Fields Virology. 5th ed. Philadelphia, USA: Wolters Kluwer and Lippincot Williams and Willkins; 2007.
2. Huang Z., Krishnamurthy S., Panda A., Samal S.K. Newcastle disease virus V protein is associated with viral pathogenesis and functions as an alpha interferon antagonist. J. Virol. 2003; 77 (16): 8676-85.
3. Park M.S., Garcia-Sastre A., Cros J.F., Basler C.F., Palese P. Newcastle disease virus V protein is a determinant of host range restriction. J. Virol. 2003; 77 (17): 9522-32.
4. de Leeuw O.S., Koch G., Hartog L., Ravenshorst N., Peeters B.P. Virulence of Newcastle disease virus is determined by the cleavage site of the fusion protein and by both the stem region and globular head of the haemagglutinin-neuraminidase protein. J. Gen. Virol. 2005; 86 (Pt. 6): 1759-69.
5. Morrison T.G. Structure and function of a paramyxovirus fusion protein. Biochim. Biophys. Acta. 2003; 1614 (1): 73-84.
6. Nagai Y., Inocencio N.M., Gotoh B. Paramyxovirus tropism dependent on host proteases activating the viral fusion glycoprotein. Behring. Inst. Mitt. 1991; (89): 35-45.
7. Tayeb S., Zakay-Rones Z., Panet A. Therapeutic potential of oncolytic Newcastle disease virus a critical review. Oncolytic. Virother. 2015; 4: 49-62.
8. Matveeva O.V., Guo Z.S., Senin V.M., Senina A.V., Shabalina S..A, Chumakov P.M. Oncolysis by paramyxoviruses: preclinical and clinical studies. Mol. Ther. Oncolytics. 2015; 2.
9. Ring C.J. Cytolytic viruses as potential anti-cancer agents. J. Gen. Virol. 2002; 83 (Pt. 3): 491-502.
10. Cuadrado-Castano S., Sanchez-Aparicio M.T., García-Sastre A., Villar E. Thetherapeutic effect of death: Newcastle disease virus and its antitumor potential. Virus. Res. 2015; 209: 56-66.
11. Zhirnov O.P., Vorobjeva I.V., Saphonova O.A., Poyarkov S.V., Ovcharenko A.V., Anhlan D. et al. Structural and evolutionary characteristics of HA, NA, NS and M genes of clinical influenza A/H3N2 viruses passaged in human and canine cells. J. Clin. Virol. 2009; 45 (4): 322-33.
12. Böttcher-Friebertshäuser E., Lu Y., Meyer D., Sielaff F., Steinmetzer T., Klenk H.D. et al. Hemagglutinin activating host cell proteases provide promising drug targets for the treatment of influenza A and B virus infections. Vaccine. 2012; 30 (51): 7374-80.
13. Zhirnov O.P., Matrosovich T.Y., Matrosovich M.N., Klenk H.D. Aprotinin, a protease inhibitor, suppresses proteolytic activation of pandemic H1N1v influenza virus. Antivir. Chem. Chemother. 2011; 21 (4): 169-74.
14. Zhirnov O.P., Konakova T.E., Wolff T., Klenk H.D. NS1 protein of influenza A virus down-regulates apoptosis. J. Virol. 2002; 76 (4): 1617-25.
15. Zhirnov O. P., Ikizler M. R., Wright P. Cleavage of influenza A virus hemagglutinin in human respiratory epithelium is cell-associated and sensitive to exogenous antiproteases. J. Virol. 2002; 76 (17): 8682-9.
16. Жирнов О.П., Букринская А.Г. Изучение белков вируса Сендай: протеолитическая активность в составе вирусных частиц. Вопросы вирусологии. 1977; (5): 571-8.
17. Zhirnov O.P., Ovcharenko A.G., Bukrinskaya A.G. Myxovirus replication in chicken embryos can be suppressed by aprotinin due to the blockage of viral glycoprotein cleavage. J. Gen. Virol. 1985; 66 (Pt. 7): 1633-8.
18. Szabo R., Bugge T.H. Membrane-anchored serine proteases in vertebrate cell and developmental biology. Annu. Rev. Cell. Dev. Biol. 2011; 27: 213-35.
19. Murray A.S., Varela F.A., List K. Type II transmembrane serine proteases as potential targets for cancer therapy. Biol. Chem. 2016; 397 (9): 815-26.
20. Naik S., Russell S.J. Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert. Opin. Biol. Ther. 2009; 9 (9): 1163-76.
21. Linge C., Gewert D., Rossmann C., Bishop J.A., Crowe J.S. Interferon system defects in human malignant melanoma. Cancer Res. 1995; 55 (18): 4099-104.
22. Abd-Elrahman I., Hershko K., Neuman T., Nachmias B., Perlman R., Ben-Yehuda D. The inhibitor of apoptosis protein Livin (ML-IAP) plays a dual role in tumorigenicity. Cancer Res. 2009; 69 (13): 5475-80.
23. Gurpinar E., Vousden K.H. Hitting cancers’ weak spots: vulnerabilities imposed by p53 mutation. Trends Cell. Biol. 2015; 25 (8): 486-95.
24. Goldar S., Khaniani M.S., Derakhshan S.M., Baradaran B. Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian. Pac. J. Cancer Prev. 2015; 16 (6): 2129-44.
25. Xu D.W., Zhang G.Q., Wang Z.W., Xu X.Y., Liu T.X. Autophagy in tumorigenesis and cancer treatment. Asian. Pac. J. Cancer Prev. 2015; 16 (6): 2167-75.
26. Zhirnov O.P., Klenk H.D. Human influenza viruses are proteolytically activated and do not induce apoptosis in CACO-2 cells. Virology. 2003; 313 (1): 198-212.
Problems of Virology. 2017; 62: 65-72
Paramyxoviruses activation by host proteases in cultures of normal and cancer cells
https://doi.org/10.18821/0507-4088-2017-62-2-65-72Abstract
References
1. Lamb R.A., Parks G.D. Paramyxoviridae: their viruses and their replication. In: Fields B.N., Knipe D.M., Howley P.M., eds. Fields Virology. 5th ed. Philadelphia, USA: Wolters Kluwer and Lippincot Williams and Willkins; 2007.
2. Huang Z., Krishnamurthy S., Panda A., Samal S.K. Newcastle disease virus V protein is associated with viral pathogenesis and functions as an alpha interferon antagonist. J. Virol. 2003; 77 (16): 8676-85.
3. Park M.S., Garcia-Sastre A., Cros J.F., Basler C.F., Palese P. Newcastle disease virus V protein is a determinant of host range restriction. J. Virol. 2003; 77 (17): 9522-32.
4. de Leeuw O.S., Koch G., Hartog L., Ravenshorst N., Peeters B.P. Virulence of Newcastle disease virus is determined by the cleavage site of the fusion protein and by both the stem region and globular head of the haemagglutinin-neuraminidase protein. J. Gen. Virol. 2005; 86 (Pt. 6): 1759-69.
5. Morrison T.G. Structure and function of a paramyxovirus fusion protein. Biochim. Biophys. Acta. 2003; 1614 (1): 73-84.
6. Nagai Y., Inocencio N.M., Gotoh B. Paramyxovirus tropism dependent on host proteases activating the viral fusion glycoprotein. Behring. Inst. Mitt. 1991; (89): 35-45.
7. Tayeb S., Zakay-Rones Z., Panet A. Therapeutic potential of oncolytic Newcastle disease virus a critical review. Oncolytic. Virother. 2015; 4: 49-62.
8. Matveeva O.V., Guo Z.S., Senin V.M., Senina A.V., Shabalina S..A, Chumakov P.M. Oncolysis by paramyxoviruses: preclinical and clinical studies. Mol. Ther. Oncolytics. 2015; 2.
9. Ring C.J. Cytolytic viruses as potential anti-cancer agents. J. Gen. Virol. 2002; 83 (Pt. 3): 491-502.
10. Cuadrado-Castano S., Sanchez-Aparicio M.T., García-Sastre A., Villar E. Thetherapeutic effect of death: Newcastle disease virus and its antitumor potential. Virus. Res. 2015; 209: 56-66.
11. Zhirnov O.P., Vorobjeva I.V., Saphonova O.A., Poyarkov S.V., Ovcharenko A.V., Anhlan D. et al. Structural and evolutionary characteristics of HA, NA, NS and M genes of clinical influenza A/H3N2 viruses passaged in human and canine cells. J. Clin. Virol. 2009; 45 (4): 322-33.
12. Böttcher-Friebertshäuser E., Lu Y., Meyer D., Sielaff F., Steinmetzer T., Klenk H.D. et al. Hemagglutinin activating host cell proteases provide promising drug targets for the treatment of influenza A and B virus infections. Vaccine. 2012; 30 (51): 7374-80.
13. Zhirnov O.P., Matrosovich T.Y., Matrosovich M.N., Klenk H.D. Aprotinin, a protease inhibitor, suppresses proteolytic activation of pandemic H1N1v influenza virus. Antivir. Chem. Chemother. 2011; 21 (4): 169-74.
14. Zhirnov O.P., Konakova T.E., Wolff T., Klenk H.D. NS1 protein of influenza A virus down-regulates apoptosis. J. Virol. 2002; 76 (4): 1617-25.
15. Zhirnov O. P., Ikizler M. R., Wright P. Cleavage of influenza A virus hemagglutinin in human respiratory epithelium is cell-associated and sensitive to exogenous antiproteases. J. Virol. 2002; 76 (17): 8682-9.
16. Zhirnov O.P., Bukrinskaya A.G. Izuchenie belkov virusa Sendai: proteoliticheskaya aktivnost' v sostave virusnykh chastits. Voprosy virusologii. 1977; (5): 571-8.
17. Zhirnov O.P., Ovcharenko A.G., Bukrinskaya A.G. Myxovirus replication in chicken embryos can be suppressed by aprotinin due to the blockage of viral glycoprotein cleavage. J. Gen. Virol. 1985; 66 (Pt. 7): 1633-8.
18. Szabo R., Bugge T.H. Membrane-anchored serine proteases in vertebrate cell and developmental biology. Annu. Rev. Cell. Dev. Biol. 2011; 27: 213-35.
19. Murray A.S., Varela F.A., List K. Type II transmembrane serine proteases as potential targets for cancer therapy. Biol. Chem. 2016; 397 (9): 815-26.
20. Naik S., Russell S.J. Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert. Opin. Biol. Ther. 2009; 9 (9): 1163-76.
21. Linge C., Gewert D., Rossmann C., Bishop J.A., Crowe J.S. Interferon system defects in human malignant melanoma. Cancer Res. 1995; 55 (18): 4099-104.
22. Abd-Elrahman I., Hershko K., Neuman T., Nachmias B., Perlman R., Ben-Yehuda D. The inhibitor of apoptosis protein Livin (ML-IAP) plays a dual role in tumorigenicity. Cancer Res. 2009; 69 (13): 5475-80.
23. Gurpinar E., Vousden K.H. Hitting cancers’ weak spots: vulnerabilities imposed by p53 mutation. Trends Cell. Biol. 2015; 25 (8): 486-95.
24. Goldar S., Khaniani M.S., Derakhshan S.M., Baradaran B. Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian. Pac. J. Cancer Prev. 2015; 16 (6): 2129-44.
25. Xu D.W., Zhang G.Q., Wang Z.W., Xu X.Y., Liu T.X. Autophagy in tumorigenesis and cancer treatment. Asian. Pac. J. Cancer Prev. 2015; 16 (6): 2167-75.
26. Zhirnov O.P., Klenk H.D. Human influenza viruses are proteolytically activated and do not induce apoptosis in CACO-2 cells. Virology. 2003; 313 (1): 198-212.
События
-
Журнал «Неотложная кардиология и кардиоваскулярные риски» присоединился к Elpub >>>
6 июн 2025 | 09:45 -
К платформе Elpub присоединился «Медицинский журнал» >>>
5 июн 2025 | 09:41 -
НЭИКОН принял участие в конференции НИИ Организации здравоохранения и медицинского менеджмента >>>
30 мая 2025 | 10:32 -
Журнал «Творчество и современность» присоединился к Elpub! >>>
27 мая 2025 | 12:38 -
Журналы НЦЭСМП приняты в Scopus >>>
27 мая 2025 | 12:35